Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report

With its hepatitis D program headed for a Phase III readout next year, Bluejay has accepted an acquisition offer from Mirum, adding to the buyer’s portfolio of therapies for liver diseases.

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is paying $620 million up front, including $250 million in cash and the balance in stock, to acquire privately held Bluejay Therapeutics Inc. Pending the deal’s close, Mirum will gain control of brelovitug, an anti-HBsAg antibody that is in the Phase III AZURE program to treat chronic HDV; initial top-line results are due in 2H26. In Phase II testing, the mAb led to a 100% HDV RNA response rate...